419 results about "Pulmonary acariasis" patented technology

To provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue.SOLUTION: In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective in injuring or damaging tissue, nerves and nerve endings in order to relieve disease symptoms.SELECTED DRAWING: Figure 3B

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

Pulmonary treatment devices, systems and methods of use are provided which take into account the vast tissue damage of advanced COPD sufferers and provide treatments designed specifically to treat the particularly compromised lung tissues that are present in these patients. These treatments reduce trapped air volume, tension lung tissue and enhance lung elastic recoil. In particular, a variety of embodiments of pulmonary treatment devices are provided. The devices are comprised of a shape memory material wherein the devices are able to be expanded under tension, and then are able to recoil back toward an original relaxed or resting shape as the devices are deployed into the tissue. This action causes the pulmonary treatment devices to corkscrew into damaged tissue, becoming sufficiently entwined to allow pulling of the tissue by retraction of the device. This in turn re-tensions the lung causing lung volume reduction.

Various processes, algorithms, and systems are provided herein for assisting physicians in distinguishing among related diseases, such as distinguishing connective tissue associated interstitial lung disease from idiopathic pulmonary fibrosis. Methods for generating such processes, algorithms, and systems are also disclosed. In some embodiments, a preliminary diagnosis of a set of possible diseases is obtained, along with protein count information from a patient's blood sample. Additional, patient-specific information (e.g., age, sex, etc.) may also be obtained. The data is processed by a trained machine learning algorithm, to output a differential diagnosis of which of the set of possible diseases is present for that patient. Based on the diagnosis, a treatment course can be selected, and further information can be tracked regarding the patient's outcome.

To provide compounds as new proline derivatives, and to provide a pharmaceutical composition comprising the compounds for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis, non-alcoholic steatohepatitis, interstitial lung disease and idiopathic pulmonary fibrosis.SOLUTION: There are provided new proline derivatives of formula (I) as cGAS inhibitors, or pharmaceutical compositions comprising a prodrug, a pharmaceutically acceptable salt, or a stereoisomer of the compound.SELECTED DRAWING: None

Provided herein are pharmaceutical compositions and methods for treating COPD or COPD exacerbations in subjects suffering from, for example, moderate COPD, or subjects with decreased eosinophil concentrations, or are suffering from chronic bronchitis. Also provided herein are methods of increasing trough lung function in subjects suffering from moderate COPD. In some aspects, the compound is in an inhalable pharmaceutical composition.

A computer implemented method for quantifying and predicting the progression of interstitial lung disease is disclosed herein. The method comprises obtaining at least one image based on a scan of at least a part of a patient's lung, segmenting the image to obtain a lung mask defining the periphery of the lung and to identify structures within the lung mask, and applying a weighting to the identified structures based on the relative position of the structures relative to the lung periphery to obtain a weighted score. The method may then comprise quantifying the extent of interstitial lung disease, and / or predicting the progression of interstitial lung disease, based on the weighted score.

The invention relates to a layered prediction method and system for the risk of malignant tumors related to dermatomyositis. The method comprises the following steps: collecting clinical index data of a patient suffering from dermatomyositis, the clinical index data comprising an anti-TIF1-gamma antibody detection result, an interstitial lung disease existence state, a dermatomyosis existence state, an anemia state and a dermatomyositis type; constructing a comprehensive scoring model to generate a risk stratification prediction result according to the clinical index data; the comprehensive scoring model is used for performing binary assignment on each index to obtain a score of a corresponding item; calculating the sum of scores of all indexes of the patient to obtain a total risk score; and layering the risk of the malignant tumor accompanied by the patient based on the total risk score, and outputting a risk layering result. According to the method, the cancer risk of the patient with dermatomyositis can be effectively predicted, and the reliability, convenience and practicability of layered prediction of the cancer risk are improved.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

The present invention provides compounds of formula I for the treatment of diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonosis, nonalcoholic steatohepatitis (NASH), interstitial lung disease (ILD), and idiopathic pulmonary fibrosis (IPF). JPEG2026504613000125.jpg8493 (in the formula, R 1 , R 2 , R 3 , R 4 , A, D, E, G, J, K, and L are as defined in claim 1), and prodrugs, deuterated analogs, and pharmaceutically acceptable salts thereof.

The present invention relates to the field of biomedicine. Provided are an anti-human IL-4Rα antibody or an antigen-binding fragment thereof and the use thereof. The anti-human IL-4Rα antibody comprises heavy chain complementarity determination regions HCDR1, HCDR2 and HCDR3, and light chain complementarity determination regions LCDR1, LCDR2 and LCDR3, has high affinity with human IL-4Rα, can be used for preparing an antibody drug, can be used for treating type-II inflammatory diseases, and has relatively good clinical efficacy and relatively low toxic and side effects. Further provided are a bispecific antibody against both IL-4Rα and TSLP, and the use of the antibody in the preparation of a drug for treating severe asthma, moderate to severe atopic dermatitis and chronic obstructive pulmonary disease.

An early screening system for chronic obstructive pulmonary disease based on blood routine test data. It belongs to the technical field of digital medical treatment, and specifically relates to the technical field of intelligent early screening of chronic obstructive pulmonary disease. It solves the technical problem that the generalization ability of a COPD prediction model is limited due to differences between different research data sets. The system comprises a data collection module that collects blood routine test data of a plurality of chronic obstructive pulmonary disease patients and blood routine test data of a plurality of normal personnel; a data preprocessing module that performs standardization processing on the blood routine test data to obtain a standardized data set; a screening model training module that trains N classification models using the standardized data set and calculates the prediction accuracy of each classification model; and a screening model application module that obtains the fusion weight of each model by using a normalization processing method based on the prediction accuracy of each classification model, fuses the risk scores predicted by the multiple models, and obtains a final screening result.

The invention belongs to the technical field of biological medicines, and particularly relates to application of small interfering RNA (Ribonucleic Acid) of a targeted Zyx gene. The invention provides siRNA (small interfering Ribonucleic Acid) of a targeted Zyx gene, and further provides application of the siRNA in prevention and treatment of fibrosis interstitial lung diseases. Experimental data prove that in a mouse bleomycin model, siRNA of a targeted Zyx gene can effectively improve the survival rate of a sick mouse, alveolar wall thickening, lung substantive thickening and inflammatory cell infiltration of a Zyx knock-down group are not obvious, and pathological damage caused by bleomycin is effectively relieved through knock-down of the Zyx gene; collagen fiber deposition of a Zyx knock-down group is reduced, and the transcription level of fibrosis-related genes is obviously reduced.

The invention belongs to the technical field of French window welding machining, and particularly relates to a French window multi-station synchronous welding device which comprises a base and a French window frame installed above the base, and is characterized in that a supporting plate is installed on one side of the lower end face of the base, and a servo push rod is installed at the upper end of the supporting plate; a welding adjusting assembly is installed at the piston rod end of the servo push rod and comprises a mounting frame installed at the piston rod end of the servo push rod, an inner cavity of the mounting frame is slidably connected with an L-shaped sliding frame, and a fixing rod is installed at the upper end of the L-shaped sliding frame. The French window frame has the advantages that the existing French window frame is simple in structure and convenient to use, toxic gas generated by welding is not filtered, potential safety hazards such as lung diseases are easily caused by long-time inhalation of operators, and the machining efficiency of the whole French window frame is affected by grinding and polishing of welding positions after welding is generally completed.

Aspects of the disclosure relate to compositions and methods for base editing using viral vectors. In some aspects, the disclosure provides an adenine base editor (ABE) utilizing an evolved Cas9 nickase derived from Neisseria meningitidis; and adeno-associated viruses (AAVs) comprising (or encoding) such adenine base editors. In some aspects, compositions described herein are useful for treatment of certain diseases, for example pulmonary diseases.

The invention discloses a chronic obstructive pulmonary disease mouse model induced by long-term continuous cigarette smoke exposure as well as a construction method and application thereof, and the construction method comprises the following steps: introducing cigarette smoke with constant concentration into a smoke exposure device, so that a mouse is in a cigarette smoke exposure environment for a long time and maintains normal diet and drinking; performing macroscopic characterization and microcosmic index evaluation on the mouse model with the chronic obstructive pulmonary disease until clinical symptoms of the chronic obstructive pulmonary disease appear; wherein the smoke exposure device comprises a smoke mixing box, a sealed feeding exposure box and a control box, the sealed feeding exposure box provides a cigarette smoke exposure environment, and the control box maintains the stability of the cigarette smoke exposure environment. According to the method, the occurrence cause of the chronic obstructive pulmonary disease of the mouse is simulated by optimizing exposure parameter conditions, the clinical symptoms of the chronic obstructive pulmonary disease of the mouse model are evaluated in multiple dimensions, and the method accords with the symptoms and signs of the chronic obstructive pulmonary disease, is high in similarity and good in reliability, and can be used as a disease model for research of the chronic obstructive pulmonary disease.

The invention belongs to the technical field of biological medicines, and particularly relates to an MAF vaccine as well as a preparation method and application thereof. In order to develop a nasal spray type vaccine capable of effectively preventing and treating fibrotic interstitial lung diseases and avoiding risk increase caused by local inflammatory reaction, the invention adopts two modes of taking a synthesized MAF protein as a model antigen, encapsulating the MAF protein by using a TLR7 adjuvant to form a peptide fragment vaccine or constructing an MAF adenovirus vaccine based on an adenovirus vector. Two vaccines based on the MAF target spot are successfully constructed. Animal experiment results prove that the two vaccines based on the MAF target spot have treatment and prevention effects on bleomycin-induced mouse pulmonary fibrosis models during nasal dripping immunization, and also have good safety in vivo. A good candidate vaccine is provided for future fibrotic disease prevention and treatment vaccine transformation research and clinical experiment development.

The invention belongs to the technical field of medical instruments, and discloses an oxygen-adding atomization inhaler for treating interstitial lung disease, which comprises a respirator assembly, an oxygen bottle, a liquid medicine box, a waste liquid collecting box, an atomization pump, a negative pressure suction pump and a monitoring mechanism, the respirator assembly is connected with the oxygen bottle; the liquid medicine box is communicated with the oxygen bottle; a medicine mist supply pipe is arranged on the respirator assembly; the respirator assembly is slidably provided with a buccal device; an atomizing pump is arranged on the liquid medicine box; the atomizing pump is connected with the medicine mist supply pipe and the mouth holding device; a negative pressure suction pump is arranged on the waste liquid collecting box; the respirator assembly is provided with a sputum suction hose; and a monitoring mechanism is fixedly arranged on the liquid medicine box. According to the device, the mouth holding device or the medicine mist supply pipe can be selected for oxygen adding atomization inhalation treatment, abnormal conditions of a patient can be found in time, data of a plurality of monitoring indexes are integrated for fusion and analysis, potential risks are found in time, and when it is monitored that the patient has dyspnea, medicine feeding is automatically stopped, oxygen conveying is started, and sputum can be cleared in time.

A medicament for treatment or prevention of interstitial lung disease, and of a disease or symptom accompanied by systemic sclerosis in a subject, the medicament comprising, as an effective ingredient, 1-{2-[(3S,4R)-1-{[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidin-3-yl]carbonyl}-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt or co-crystal thereof.

Chronic obstructive pulmonary disease (COPD) remains a major cause of morbidity and mortality worldwide. Acute exacerbation of COPD (AE-COPD) in patients are mostly due to respiratory infection and are associated with an inexorable decline in lung function, enhanced oedema as well as airway and systemic inflammation. Previous results show that treatment with anti-IL-20Rb blocking antibodies increased the bacterial clearance in control mice infected by S. pneumoniae and protected CS-exposed mice from bacterial infection, by decreasing the bacterial burden and the inflammatory infiltrate. Therefore there is an interest for generating monoclonal antibodies specific for IL-20Rb with a neutralizing activity for their use in the treatment of AE-COPD. The present invention fulfills this need by providing antibodies having specificity for IL-20Rb.

The present invention provides, in part, a novel small molecule PHD inhibitor having a structure according to Formula (A) or a sub-formula thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein are useful in the treatment of diseases, including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis). Acute kidney injury and chronic kidney disease).

The present invention provides new devices, systems, and methods for delivering enriched oxygen to recipients (e.g., chronically ill patients, such as COPD patients). One aspect is a more efficient portable oxygen concentrator that is configured to deliver an enriched oxygen airflow having a significantly lower overall oxygen concentration and greater overall volume administered as compared to currently marketed or known portable oxygen concentrators. Administering the lower oxygen concentration at higher volumes allows for the present portable oxygen concentrators to deliver an equivalent number of moles of oxygen as administered by traditional portable concentrators while increasing the efficiency of the system and the ability of the system to maintain the therapeutic level of oxygen concentration for a longer period.

The present invention relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione or a pharmaceutically acceptable salt thereof in the inhalation treatment of inflammatory lung diseases. The present invention particularly relates to the use of 5-amino-2,3-dihydro-1,4-phthalazinedione sodium salt for this purpose. Advantageous features of an aerosol containing 5-amino-2,3-dihydro-1,4-phthalazinedione or a pharmaceutically acceptable salt thereof and a method for producing the aerosol are disclosed. The present invention further relates to a kit for the inhalation treatment of inflammatory lung diseases.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The present disclosure relates to methods of treating COPD, in particular by administering an anti-IL-33 antibody or an antibody variant thereof at a specified dosing regimen.

The invention belongs to the field of respiratory system disease treatment, and provides application of a gymnadenia conopsea extract in preparation of a medicine for treating or preventing pulmonary edema. The embodiment of the invention proves that both the gymnadenia conopsea alcohol extract and the gymnadenia conopsea water extract can effectively improve indexes such as pulmonary edema respiratory rate, minute ventilation volume, rising tidal volume, inspiration peak flow, expiration peak flow and the like, and improve arterial blood-gas indexes and inflammatory factor level in alveolar lavage fluid. The invention provides the application of the gymnadenia conopsea alcohol extract and the gymnadenia conopsea water extract in the medicine for treating or preventing lung diseases, especially pulmonary edema for the first time, the traditional medicine gymnadenia conopsea is fully developed and utilized, and a safe and effective means is provided for treating the critical disease pulmonary edema.

This disclosure relates to a method, system, and dynamic X-ray camera for intelligent identification of chronic obstructive pulmonary disease (COPD), belonging to the field of intelligent COPD identification technology. The intelligent COPD identification method includes: acquiring one or more of the following dynamic X-ray quantitative parameters from a sequence of left lung field area parameters, right lung field area parameters, left diaphragm parameters, right diaphragm parameters, and cardiothoracic ratio parameters corresponding to multiple dynamic two-dimensional chest X-ray images during respiration; and performing intelligent COPD identification based on one or more of the dynamic X-ray quantitative parameters from the left lung field area parameters, right lung field area parameters, left diaphragm parameters, right diaphragm parameters, and cardiothoracic ratio parameters, using a preset intelligent COPD identification model. The embodiments of this disclosure can achieve intelligent identification of chronic obstructive pulmonary disease.

Novel kisspeptin-13 or KP-13 peptides and KP-13 satellites or modified peptides (KPSATs) are disclosed having improved therapeutic benefits in regulating pathophysiological changes in various tissues, particularly lung tissue. These KPSATs have improved antiproliferative effects and non-cytotoxic effects on airway smooth muscle cells and tissue.

A system configured for use in diagnosing a respiratory health condition of a patient comprising: processor configured to: provide image data of lungs of a patient; derive two or more features from the image data; combine the two or more features to produce a composite feature; use the composite feature to diagnose the presence of a respiratory health condition in the lungs of the patient.

The present invention provides methods and compositions for the treatment of chronic lung disease (CLD), comprising administering to a subject in need of treatment a composition comprising insulin-like growth factor-1 (IGF-1).